New guidelines related to pulmonary embolism could provide a boost for Boston Scientific (NYSE: BSX) and Stryker (NYSE: SYK), among others. Yesterday, the American Heart Association (AHA) and American College of Cardiology (ACC) joint committee updated its guidelines for pulmonary embolism (PE). This marks the first update since the AHA last … [Read more...] about AHA, ACC issue guidelines for pulmonary embolism that affect Boston Scientific, Stryker
Inari Medical
Stryker’s Inari Medical launches next-gen thrombectomy system
Inari Medical — now part of Stryker — today announced the launch of its next-generation InThrill thrombectomy system. The company describes InThrill as the first and only purpose-built small vessel and arteriovenous (AV) access thrombectomy system that can deliver fast, complete luminal clot removal. Inari says its second-generation, 8-Fr, … [Read more...] about Stryker’s Inari Medical launches next-gen thrombectomy system
Stryker’s Inari Medical launches Artix thrombectomy system
Inari Medical — now part of Stryker — announced that it launched its Artix thrombectomy system for arterial thrombectomies. The company built Artix for the distinct needs of the peripheral arterial system, according to a news release. It marks Inari's inaugural entry into the arterial space. The combined aspiration plus mechanical … [Read more...] about Stryker’s Inari Medical launches Artix thrombectomy system
Inari Medical has positive ClotTriever data
Inari Medical (Nasdaq:NARI) announced positive two-year interim results from the CLOUT registry evaluating its ClotTriever system. Principal investigator Dr. David Dexter of Sentara Vascular Specialists in Norfolk, Virginia, presented the data at the American Venous Forum. Results represent the largest prospective, multi-center, two-year … [Read more...] about Inari Medical has positive ClotTriever data
Inari Medical plans to buy LimFlow Medical for up to $415M
Inari Medical today announced a definitive agreement to purchase LimFlow Medical for up to $415 million. The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI). San Jose, California–based Inari said it expects to complete the … [Read more...] about Inari Medical plans to buy LimFlow Medical for up to $415M
Inari Medical to bring in up to $186.3M in stock offering
Inari Medical (Nasdaq:NARI) announced that it priced an underwritten public offering worth up to $186.3 million in proceeds. Irvine, California-based Inari Medical’s offering includes 2 million shares of its common stock at a public offering price of $81 per share before underwriting discounts and commissions. In addition, the company granted … [Read more...] about Inari Medical to bring in up to $186.3M in stock offering
